The Hallmarks of Aging: What the Research Describes

This content is educational. It describes the biological processes that research has identified as drivers of aging. It is not medical advice and is not a guide to anti-aging intervention.

Why this matters

For most of biomedical history, aging was treated as a single inevitable process — entropy applied to a body. Over the past three decades, that view has shifted. Research has identified specific, measurable cellular and molecular processes that together produce what we observe as aging. These processes are partially independent, partially interacting, and increasingly targetable.

In 2013, a landmark paper by Carlos López-Otín and colleagues synthesised the field into a framework: the nine hallmarks of aging [López-Otín et al. 2013]. The framework was updated in 2023 to twelve hallmarks reflecting a decade of new research [López-Otín et al. 2023].

This page describes what each hallmark is, what research has measured about its contribution to aging, and where active research and pharmaceutical development sits. It is not a guide to interventions — most of the work in this area is still pre-clinical or in early human trials.

What the hallmarks framework provides

The framework defines a hallmark of aging as a process that meets three criteria:

1. It manifests during normal aging
2. Its experimental aggravation accelerates aging
3. Its experimental amelioration retards normal aging or extends healthy lifespan

This is a high bar. It requires not just association with aging but causal contribution demonstrated in experimental models. The hallmarks are the processes that have crossed it.

The 2023 update organised the hallmarks into three categories: primary causes of damage, antagonistic responses to that damage, and integrative consequences when responses fail.

The primary hallmarks (causes of damage)

Genomic instability

DNA accumulates damage continuously from oxidative metabolism, UV radiation, replication errors, and other sources. Repair mechanisms become less effective with age. Accumulated mutations contribute to cellular dysfunction, cancer risk, and tissue degeneration.

Research has measured genomic instability through somatic mutation burdens, DNA damage markers, and chromosomal aberrations in aging tissues [Vijg & Suh 2013].

Telomere attrition

Telomeres — repetitive DNA sequences at chromosome ends — shorten with each cell division. When telomeres become too short, cells enter replicative senescence. Telomere length is a measurable biomarker associated with aging and age-related disease, though the relationship to lifespan in humans is more complex than initially proposed [Blackburn et al. 2015].

Epigenetic alterations

The epigenome — the set of chemical modifications that determine which genes are active — changes systematically with age. Specific DNA methylation patterns can predict chronological age with high accuracy (the epigenetic clocks: Horvath, Hannum, GrimAge, PhenoAge) [Horvath 2013; Levine et al. 2018]. Some of these patterns appear to be reversible in experimental settings.

Loss of proteostasis

Cells continually produce, fold, and degrade proteins. The machinery that maintains this balance — chaperones, the proteasome, autophagy — declines with age. Misfolded protein accumulation underlies Alzheimer's, Parkinson's, and other age-related neurodegenerative diseases [Hipp et al. 2019].

Disabled macroautophagy (added in 2023)

Autophagy — the cellular recycling process that breaks down damaged proteins and organelles — declines with age. The 2023 update separated this from the broader proteostasis hallmark to reflect its specific role and the rapidly growing intervention literature [Aman et al. 2021].

The antagonistic hallmarks (responses to damage)

Deregulated nutrient sensing

The signalling pathways that respond to nutrient availability — insulin/IGF-1, mTOR, AMPK, sirtuins — change activity with age. Many of the most-studied longevity interventions in model organisms work through these pathways. Caloric restriction extends lifespan in multiple species and works partly through these signalling changes [Fontana et al. 2010].

Mitochondrial dysfunction

Mitochondria — the cellular energy producers — become less efficient with age. Reactive oxygen species production rises, ATP output falls, and damaged mitochondria accumulate. The "free radical theory of aging" originated here, though the modern picture is more nuanced than simply "more antioxidants extend life" [Sun et al. 2016].

Cellular senescence

Cells that have ceased dividing but have not been cleared from tissue accumulate with age. Senescent cells secrete inflammatory factors (the senescence-associated secretory phenotype, SASP) that affect neighbouring tissues. Clearing senescent cells in mice has extended healthy lifespan in landmark studies [Baker et al. 2016]. Senolytic drugs — compounds that selectively kill senescent cells — are in active human trials.

The integrative hallmarks (consequences when responses fail)

Stem cell exhaustion

Tissue-specific stem cells become depleted or dysfunctional with age, impairing regeneration. Visible in hair greying, slowed wound healing, reduced immune renewal, and many other observable aging features [Goodell & Rando 2015].

Altered intercellular communication

Aging changes how cells communicate — through inflammatory cytokines, hormones, exosomes, and direct contact. Chronic low-grade inflammation ("inflammaging") is a particularly well-studied aspect [Franceschi et al. 2018].

Chronic inflammation (added in 2023)

The 2023 update promoted inflammaging from a sub-feature to a standalone hallmark. Persistent low-grade inflammation across multiple tissues has been linked to virtually every major age-related disease [Furman et al. 2019]. Omega-3 fatty acids (EPA and DHA) have been studied for their role in modulating inflammatory signalling pathways; Proco's Omega-3 (EPA 180 mg / DHA 120 mg) uses the EPA/DHA ratios studied in cardiovascular and inflammation trials.

Dysbiosis (added in 2023)

The gut microbiome shifts with age in characteristic patterns. The 2023 update added microbiome dysregulation as a hallmark, reflecting evidence that microbial composition affects host inflammation, metabolism, and brain function [Wilmanski et al. 2021].

Why the framework matters for consumer health

The hallmarks framework has practical implications for how to read longevity research:

1. Aging is multi-causal. No single intervention addresses all hallmarks. Claims that a single supplement or protocol "reverses aging" are inconsistent with the biology — even well-evidenced interventions typically affect a subset.

2. Mechanism-to-clinical gaps are large. Many interventions show effects on individual hallmarks in cells or mice. Demonstrating that they extend healthy human lifespan is a much higher bar that few interventions have cleared.

3. The most-discussed interventions target specific hallmarks. Rapamycin and caloric restriction → nutrient sensing. Senolytics → cellular senescence. NAD+ precursors → mitochondrial function. Metformin → multiple pathways. Each has hallmark-specific evidence and hallmark-specific limitations.

4. Biomarker measurement is improving. Epigenetic clocks, senescence markers, inflammatory profiles, and microbiome composition are all measurable. The connection between moving these biomarkers and extending healthy lifespan in humans is still being established.

What the research has and hasn't established

Established with strong evidence:

• The twelve hallmarks each contribute to aging in model organisms
• Modifying individual hallmarks in mice extends healthspan
• Aging is plastic — not fixed at any specific rate
• Multiple hallmark-targeting interventions exist that show effects in human biomarkers

Less established:

• Whether modifying biomarkers translates to lifespan extension in humans
• The relative contribution of each hallmark to overall aging
• Whether combination interventions produce additive, synergistic, or competing effects
• Long-term safety of most candidate interventions in healthy adults

Active human trials in 2024-2026:

• TAME (Targeting Aging with Metformin) — testing whether metformin delays multiple age-related diseases
• Multiple senolytic trials in osteoarthritis and pulmonary fibrosis
• Rapamycin trials in healthy adults at low doses
• NAD+ precursor trials for various age-related outcomes
• Cellular reprogramming trials (Altos Labs, Calico, others) — earliest stages

What Proco's editorial position is

The longevity research field has produced real, well-grounded mechanistic findings. It has also produced a marketing layer that often outpaces the clinical evidence. Reading longevity content well means distinguishing:

• Hallmark-level claims (well-supported by basic research)
• Biomarker-level claims (often well-supported)
• Human outcome claims (much weaker for most interventions)

A supplement marketed as "targeting cellular senescence" may be supported at the mechanistic level and unsupported at the human-outcome level — both can be true simultaneously. Honest evaluation requires both.

For readers interested in interventions in this space: the field is moving fast, the published research is genuinely informative, and the marketing claims should be checked against the underlying evidence for the specific intervention. The Scanner is one tool for that work for supplement-based interventions.

Related Proco pages

• Healthspan vs lifespan: what longevity research measures
• How to read a clinical trial
• The wellness economy in 2026

Sources

Proco provides educational, research-based information. This page describes the biology of aging as researchers understand it. It is not medical advice. Many candidate interventions discussed in the longevity research field are unproven for human use and some may carry risks. Consult a qualified healthcare professional before considering any intervention.

Frequently asked questions

What are the hallmarks of aging?

The hallmarks of aging are specific, measurable cellular and molecular processes that research has identified as drivers of ageing. A landmark 2013 paper by Carlos Lopez-Otin and colleagues synthesised the field into nine hallmarks, and a 2023 update expanded this to twelve. They are organised into primary causes of damage, antagonistic responses to that damage, and integrative consequences when those responses fail.

What counts as a hallmark of aging?

The framework sets a high bar: a process must manifest during normal ageing, its experimental aggravation must accelerate ageing, and its experimental amelioration must retard ageing or extend healthy lifespan. This requires not just association with ageing but causal contribution demonstrated in experimental models. The hallmarks are the processes that have crossed that bar.

Can a single supplement reverse aging?

The biology described in the hallmarks framework suggests ageing is multi-causal, so claims that one supplement or protocol reverses ageing are inconsistent with it. No single intervention addresses all hallmarks, and even well-evidenced interventions typically affect only a subset. Many candidate interventions show effects on individual hallmarks in cells or mice, but demonstrating extended healthy human lifespan is a much higher bar.

What were the new hallmarks added in 2023?

The 2023 update expanded the framework from nine hallmarks to twelve, adding disabled macroautophagy, chronic inflammation, and dysbiosis. Disabled autophagy was separated from broader proteostasis, inflammaging was promoted from a sub-feature to a standalone hallmark, and gut microbiome dysregulation was added to reflect evidence that microbial composition affects host inflammation, metabolism, and brain function.